semaglutide glp-1 ozempic in huntington harbor GLP-1s Seven reforms to increase access

Aleksandr Shapsis, MD

Glucagonlike peptide 1 receptor agonists (GLP1RA) are commonly used as treatment for type 2 diabetes mellitus and obesity

A no-cook GLP-1 meal plan PDF for low-energy, nausea, and exhausted post-dose days

#Retatrutide is a #promising #weight #loss medication developed by Eli Lilly, currently in Phase 3 clinical trials

During the study period, 113 patients (8-year cumulative incidence 9.3%) compared to 130 non-surgical patients (8-year cumulative incidence 11.3%) suffered from MACE or all-cause mortality (HR 0.76, 95%CI 0.590.98), and 69 patients (8-year cumulative incidence 5.1%) compared to 92 non-surgical patients (8-year cumulative incidence 7.6%) suffered from a non-fatal MACE (HR 0.68, 95%CI 0.490.93)